Abstract
Many countries have national guidelines for performing economic evaluations in healthcare.1 These guidelines should ensure the comparability and quality of such evaluations, which should facilitate making well informed policy decisions regarding reimbursement of interventions. Given the developments in both the methodology and policy context of economic evaluation of healthcare interventions, these guidelines require periodical revision. Recently, the Dutch National Health Care Institute issued new guidance for economic evaluations in healthcare [1]. The new guidelines update and replace three separately published previous guidelines: those for pharmacoeconomic evaluation (latest version 2006), outcomes research (latest version 2008) as well as the Dutch costing manual (latest version 2010). In this editorial, we highlight the distinguishing features of the new Dutch guidelines. Moreover, we highlight which developments, in our opinion, are desirable in coming updates, but are still in development or controversial.
Original language | English |
---|---|
Pages (from-to) | 1071-1074 |
Number of pages | 4 |
Journal | Pharmacoeconomics (Print) |
Volume | 34 |
Issue number | 11 |
DOIs | |
Publication status | Published - 2016 |
Research programs
- EMC NIHES-05-63-02 Quality